

Venue: Exhibition, Ground Level
Presentation: Wednesday 3 July, 12:30-14:30
The Poster Exhibition is open from Mon 1 - Wed 3 July from 10:00 to 18:30. Posters will be displayed for the duration of the conference.

Authors will stand by their posters between 12:30 and 14:30 on their assigned day of presentation to answer questions and provide further information on their study results.

Track A > Basic Sciences

- PE436-439 Regulation of viral gene expression and replication**
- WEPE436 **Suppression of HIV-1C virus production in human PBMCs by dsRNA induced chromatin remodeling of LTR promoter**
A. Singh, J.K. Palanichamy, P. Ramalingam, M.A. Kassab, M. Bhagat, R. Andrabi, K. Luthra, S. Sinha, P. Chattopadhyay
 India
- WEPE437 **CCR6 functions as a new coreceptor for limited primary human and simian immunodeficiency viruses**
S. Islam, A. Hoque, N. Shimizu, A. Jinno-Oue, A. Tanaka, H. Hoshino
 Bangladesh
- WEPE438 **HIV proviral RNA expressed within introns of cellular genes participates in alternative RNA splicing to yield chimeric HIV-cell mRNAs that express Tat**
S. Sonza, J. Jacobson, T. Mota, J. Howard, P. Revill, S. Lewin, D. Purcell
 Australia
- WEPE439 **Single-molecule tracking of cytoplasmic HIV-1 RNA reveals diffusion-based transport and Gag-independent RNA:RNA interaction**
J. Chen, D. Grunwald, L. Sardo, O. Nikolaitchik, V. Pathak, W.-S. Hu
 United States
-
- PE440-442 Cellular factors necessary for HIV replication**
- WEPE440 **Involvement of human topoisomerase II isoforms in the strand transfer events of HIV-1 reverse transcription**
S. Lokeswara Balakrishna, A.K. Kondapi
 India
- WEPE441 **Restriction of HIV-1 infection in dendritic cells avoids induction of IFN- α -mediated responses and reduces chemokine expression: impact on viral escape and establishment of CD4 reservoirs**
E. Calonge, J. Garcia-Perez, M. Bermejo, N. Gonzalez, M. Coiras, A. Muñoz, L. Jimenez, J. Alcami
 Spain
- WEPE442 **Suppression of HIV-1 replication by targeting viral RNA processing**
A. Cochrane, R. Wong, M. Calimano, A. Mao
 Canada
-
- PE443-445 Cellular and tissue reservoirs**
- WEPE443 **Factors associated with a low HIV reservoir in patients with prolonged suppressive antiretroviral therapy**
S. Fourati, R. Calin, G. Carcelain, P. Flandre, C. Soulie, S. Lambert-Niclot, Z. Ait-Arkoub, R. Tubiana, M.A. Valantin, B. Autran, C. Katlama, V. Calvez, A.-G. Marcelin
 France

- WEPE444 **Differential impact of APOBEC3-driven mutagenesis on HIV evolution in diverse anatomical compartments**
S. Fourati, S. Lambert-Niclot, C. Soulie, M. Wirden, B. Descours, I. Malet, M.A. Valantin, R. Tubiana, A. Simon, C. Katlama, G. Carcelain, V. Calvez, A.-G. Marcelin
 France
- WEPE445 **Longitudinal analysis of infection frequencies and genetic makeup of intracellular HIV-1 from tissue compartments during long-term suppressive therapy**
S. Eriksson, L. Josefsson, E. Sinclair, H. Hatano, W. Shao, P. Hunt, M. Somsouk, P. Bacchetti, S. Deeks, P. Lemey, F. Hecht, S. Palmer
 Australia
-
- PE446 Mechanisms of HIV persistence**
- WEPE446 **Evaluation of residual HIV-1 replication among individuals receiving different antiretroviral treatment regimens**
L. Bertoni Giron, S. Tenore, R. Gabriel, M.C. Araripe Sucupira, R. Sobhie Diaz
 Brazil
-
- PE447 Early virus-host interactions**
- WEPE447 **Characterization of integrin $\alpha 4\beta 7$ polymorphisms and associated HIV-1 V2 domain signature analysis of in HIV+ patients presenting different profiles of disease progression**
S. Hait, E. Machado, E.J.A.M. Soares, E. Sprinz, M.A. Soares
 Brazil
-
- PE448 Viral determinants of pathogenesis**
- WEPE448 **HIV-1 subtype BF leads to faster CD4+ T cell loss, compared to subtype B**
L.F. Tarosso, S.S. Sanabani, S.P. Ribeiro, M.M. Sauer, M.C. Sucupira, R.S. Diaz, E.C. Sabino, E.G. Kallas
 Brazil
-
- PE449-451 Acute and early HIV/SIV infection**
- WEPE449 **CD4 T cell subpopulations and IL7-R α expression kinetics in primary and chronic HIV-infected patients treated with a maraviroc-based art**
M. Ripa, S. Nozza, D. De Battista, M. Malnati, S. De Biasi, A. Cossarizza, M. Pogliaghi, S. Chiappetta, A. Lazzarin, G. Tambussi
 Italy
- WEPE450 **Analysis of HLA-restricted HIV-specific CD8 T cell responses and viral adaptation in patients with acute HIV infection prior to full seroconversion**
N. Keane, C.-A. Almeida, A. Chopra, D. Cooper, S. Mallal, M. John
 Australia
- WEPE451 **Subsets of regulatory T cells in primary HIV infection; 'Tr-1 like' Foxp3- cells are the main producers of IL-10**
C. Didier, M. Chevalier, G. Petitjean, P.-M. Girard, F. Barré-Sinoussi, D. Scott-Algara, L. Weiss
 France
-
- PE452 Systems biology to approach HIV/AIDS**
- WEPE452 **Targeted transcriptomic analysis reveals cellular factors responsible for the suppressive effect of cannabinoids on HIV-1 replication**
I. Tasovski, J. Purushe, N. Ristic, M.P.S. Chin
 United States

WEPE453	<p>Mechanisms of T cell depletion and reconstitution</p> <p>The role of single nucleotide polymorphisms (SNPs) in TLR4 and CD14 genes on CD4 T-cell recovery in HIV-infected patients receiving antiretroviral therapy</p> <p><i>Y.K. Yong, R. Rajasuriar, A. Solomon, P. Velayudham, T. Spelman, C. Fairley, J. Hoy, P. Cameron, A. Kamarulzaman, S.R. Lewin</i> Malaysia</p>
PE454	<p>Gut and microbial translocation</p> <p>HAART controllers have elevated markers of microbial translocation compared to elite controllers and viremic controllers despite lower levels of immune activation</p> <p><i>S. Desai, E. Golub, J. Zhang, M. Cohen, R. Greenblatt, K. Anastos, M. Young, M. Nowicki, P. Norris, H. Minkoff, A. Landay, S. Gange</i> United States</p>
WEPE455	<p>PE455</p> <p>Correlates and biomarkers of disease progression</p> <p>Evolution of neutralizing antibodies in acute heterosexually acquired HIV-1C infection in Botswana</p> <p><i>K. Bedi, S. Mpoloka, S. Gaseitsiwe, R. Musonda, J. Makhema, V. Notvisky, M. Essex, T. Mdlulza</i> Botswana</p>
WEPE456	<p>PE456</p> <p>Elite controllers</p> <p>In vivo analysis of the replication capacity and pathogenic potential of HIV primary isolates from an elite suppressor</p> <p><i>M. Swanson, M. Salgado, C. Pohlmeier, R. Buckheit III, J. Blankson, J.V. Garcia-Martinez</i> United States</p>
WEPE457	<p>PE457-459</p> <p>HIV-hepatitis virus interactions</p> <p>HIV/AIDS co-infection with the hepatitis B and C viruses in Brazil</p> <p><i>S. Oliveira, G.F. Mendes Pereira, E. Hamann, L.D. Amorim</i> Brazil</p>
WEPE458	<p>Decline in serum 25-OH vitamin D levels in HIV-hepatitis B virus (HBV) co-infected patients with after long term antiretroviral therapy</p> <p><i>T. Apornpong, R.A. Ramautarsing, S. Ubolyam, P. Tangkijvanich, J. Ananworanich, J. Lange, G. Matthews, S. Lewins, K. Ruxrungham, A. Avihingsanon, HIV-NAT 105Study Team</i> Thailand</p>
WEPE459	<p>Transient elastography compared to liver biopsy in liver fibrosis stage assessment</p> <p><i>B. Roca, V. Torres, E. Resino, M.A. Mendoza, M. Cerezo</i> Spain</p>
WEPE460	<p>PE460-461</p> <p>Tuberculosis and other mycobacteria</p> <p>Use of cytokines and chemokines to detect mycobacteria tuberculosis infection in HIV-infected individuals</p> <p><i>Z.B. Machuki, J. Oyugi, G. Ochanda, J. Sule, F. Mutua, S. Kiazky-Koesters, B.T. Ball, A.O. Anzala</i> Kenya</p>
WEPE461	<p>Multimodal nanoparticles for targeted drug delivery and immunotherapy in tuberculosis</p> <p><i>A. Dube, J.L. Reynolds, W.-C. Law, P.N. Prasad, G. Morse, C. Maponga</i> Zimbabwe</p>

WEPE462	<p>PE462</p> <p>Interactions of HIV with other pathogens</p> <p>Bonafide, type-specific human papillomavirus persistence among HIV-positive pregnant women from Brazil: predictive value for cytological abnormalities</p> <p><i>A. Meyrelles, J. Siqueira, C. Hofer, T. Costa, A. Azevedo, P. Passos, A. Cavalcante, H. Seuanez, R. Luiz, G. Almeida, M. Soares, E. Soares, E. Machado</i> Brazil</p>
---------	---

Track B > Clinical Sciences

WEPE463	<p>PE463-464</p> <p>HIV associated opportunistic infections (excluding tuberculosis)</p> <p>Pneumocystis pneumonia can be diagnosed by quantitative detection of pneumocystis jirovecii in saliva samples by real time PCR in patients with HIV infection</p> <p><i>T. Aoki, K. Teruya, K. Tsukada, H. Gatanaga, Y. Kikuchi, S. Oka</i> Japan</p>
WEPE464	<p>Impact of antiretrovirals on the incidence of opportunistic infections in resource-limited settings: a systematic review and meta-analysis</p> <p><i>A. Low, G. Gavriilidis, N. Larke, M.-R. Lajoie, O. Drouin, J. Stover, L. Muhe, P. Easterbrook</i> Switzerland</p>
WEPE465	<p>PE465-475</p> <p>Tuberculosis</p> <p>A study evaluating the role of fine needle aspiration cytology in HIV associated lymphadenopathy</p> <p><i>N. Kumar, B.B. Gupta, B.B. Rewari</i> India</p>
WEPE466	<p>Reversion and conversion of interferon-gamma release assay results in HIV-1-infected individuals</p> <p><i>M.C. Aichelburg, T. Reiberger, F. Breitenecker, A. Makristathis, A. Rieger</i> Austria</p>
WEPE467	<p>The utilization of the geneXpert MTB/RIF technology in increasing tuberculosis case finding among HIV-infected prisoners in Malaysia: implications for policy changes</p> <p><i>H. Al-Darraj, S.N.H. Abd Razak, A. Kamarulzaman</i> Malaysia</p>
WEPE468	<p>Comparable virological response among HIV/TB co-infected patients on nevirapine and efavirenz-based ART regimen in Kota Bharu, Malaysia</p> <p><i>N. Noridah, M.J. Anilawati, M. Mahiran</i> Malaysia</p>
WEPE469	<p>Potential impact of the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) on the tuberculosis (TB)/HIV co-epidemic in selected Sub-Sahara African countries</p> <p><i>V. Lima, R. Granich, B. Williams, P. Phillips, J. Montaner</i> Canada</p>
WEPE470	<p>Rifabutin pharmacokinetics when coadministered with lopinavir/ritonavir in HIV-infected patients with tuberculosis in Viet Nam: results of ANRS12150b cross-over clinical trial</p> <p><i>N. Huy Dung, A. Barrail-Tran, N. Thi Ngoc Lan, N. Hong Duc, N. Thi Nguyet Thu, N. Ngoc Lan, D. Laureillard, T. Thi Xuan Lien, L. Borand, C. Quillet, C. Connolly, D. Lagarde, A. Pym, C. Lienhardt, A.-M. Taburet, A.D. Harries</i> France</p>

WEPE471	<p>Pharmacokinetics of anti-tuberculosis drugs in South African children</p> <p><i>H. Hiruy, C. Mbowane, J. Adamson, T. Ngotho, T. Gumbo, W. Bishai, P. Jeena</i> United States</p>	WEPE481	<p>Prevalence, risk factors of isolated antibody to hepatitis B core antigen and occult hepatitis B infection in HIV-1-infected pregnant women and risk of perinatal transmission</p> <p><i>W. Khamduang, N. Ngo-Giang-Huong, C. Gaudy-Graffin, G. Jourdain, W. Suwankornsakul, T. Jarupanich, V. Chalermopolprapa, S. Nanta, N. Puarattana-Aroonkorn, S. Tonmat, M. Lallemand, A. Goudeau, W. Sirirungsri, the Program for HIV Prevention and Treatment (PHPT-2) Group</i> Thailand</p>
WEPE472	<p>Patterns of resistance to anti-tuberculosis drugs in Zimbabwe - an analysis of laboratory-based surveillance data, 2008-2011</p> <p><i>S. Nqwende, L. Kuonza, E. Munemo, R. Simbi, S. Zinyowera</i> Zimbabwe</p>	WEPE482	<p>Impact of tenofovir (TDF)-containing antiretroviral treatment (ART) modifications to other anti-hepatitis B virus (HBV) regimens in patients co-infected with HIV-HBV</p> <p><i>A. Boyd, J. Gozlan, S. Maylin, P. Miallhes, C. Lascoux-Combe, C. Delaugerre, P.-M. Girard, K. Lacombe</i> France</p>
WEPE473	<p>Operating characteristics of an intensified tuberculosis case finding tool in Rwandan HIV care and treatment services</p> <p><i>K. Turinawe, G. Vandebriel, D. Lawrence, E. Uwinkindi, P. Mutwa, E. Pevzner, K. Boer, V. Mugisha, S. Nsanzimana, A. Howard, M. Gasana</i> Rwanda</p>	WEPE483	<p>Missed opportunities for preventing hepatitis B infection in childbearing women with HIV in Ukraine</p> <p><i>C. Thorne, H. Bailey, R. Tereschenko, I. Adeyanova, E. Kulakovskaya, L. Ostrovskaya, R. Malyuta, Ukraine Cohort of HIV-Infected Childbearing Women</i> United Kingdom</p>
WEPE474	<p>Cutaneous adverse drug reaction among HIV-infected patients starting antituberculosis treatment</p> <p><i>A. Widhani, E. Yuniastuti, S. Djauzi</i> Indonesia</p>		
WEPE475	<p>Tuberculosis burden is a barrier to starting isoniazid preventive therapy in HIV-infected children enrolled in care in Nairobi, Kenya</p> <p><i>J. Houston, C. Muriithi, W. Mbogo, A. Langat, M. Muchiri, V. Maina, A. Njoroge, L. Nganga, S. Modi</i> United States</p>		
PE476-477	<p>Other bacterial infections malaria and parasitic infections</p>		
WEPE476	<p>Bacteremias in HIV patients: 24 years of follow up. What has it changed?</p> <p><i>C. Galera, C. Redondo, J. Martinez, J. Oliva, F. Rodriguez, G. Poza</i> Spain</p>	PE484-491	<p>Hepatitis C</p>
WEPE477	<p>Invasive pneumococcal diseases in the era of HAART in Japan: epidemiologic and clinical perspectives</p> <p><i>Y. Yanagawa, K. Watanabe, H. Gatanaga, Y. Kikuchi, S. Oka</i> Japan</p>	WEPE484	<p>HCV treatment in children and young adults with HIV/HCV co-infection in Europe</p> <p><i>A. Turkova, C. Thorne, L. Galli, T. Goetghebuer, M. de Martino, C. Oprea, J.T. Ramos Amador, C. Giaquinto, European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) in EuroCoord</i> United Kingdom</p>
PE478-483	<p>Hepatitis B and D</p>	WEPE485	<p>Efficacy and tolerance of telaprevir in HIV-HCV genotype 1 co-infected patients failing previous anti-HCV therapy: 24-week results</p> <p><i>K. Lacombe, N. Valin, H. Stitou, J. Gozlan, V. Thibault, A. Boyd, J.-M. Poirier, J.-L. Meynard, M.-A. Valantin, J. Bottero, P.-M. Girard</i> France</p>
WEPE478	<p>Response to hepatitis B vaccine among HIV-infected adults in Vietnam</p> <p><i>T. Pollack, D. Colby, L.T.T. Trang, M.D.A. Thi, P.T. Thuy</i> United States</p>	WEPE486	<p>PegIFN-alfa-2a and ribavirin in HIV-HCV co-infected patients with persistently normal aminotransferase levels: final results of the CONTRA study</p> <p><i>M.A. von Wichmann, M. Santin, F. Rodriguez Arondo, K. Aguirrebengoa, J. Gonzalez, I. Santos, M. Roget, J. Mallolas, S. Reus, J. Guardiola, C. Richart, J. Portu, A. Ocampo, CONTRA Study Group</i> Spain</p>
WEPE479	<p>Serologic persistent following infant HBV vaccination and immunogenicity following one dose revaccination in HIV-infected children and adolescents</p> <p><i>P. Angkhananukit, S. Saihongthong, K. Lapphra, K. Chokephaibulkit</i> Thailand</p>	WEPE487	<p>Correlation of transient elastography with APRI, FIB-4 and Forns indexes in HIV/HCV co-infected patients</p> <p><i>A. Mena, M. Vares, B. Pernas, A. Castro, S. López, P. Vázquez, L. Morano, J. Baliñas, J.D. Pedreira</i> Spain</p>
WEPE480	<p>Transient or low-level replication is common in HIV-HBV co-infected patients treated with long-term tenofovir</p> <p><i>A. Boyd, P. Miallhes, C. Lascoux-Combe, S. Maylin, J. Gozlan, C. Delaugerre, P.-M. Girard, K. Lacombe</i> France</p>	WEPE488	<p>Current distribution of HCV genotypes among HCV-infected patients in northern Thailand</p> <p><i>P. Treesuwan, S. Intorasoot, P. Leechanachai, T. Samleerat</i> Thailand</p>
		WEPE489	<p>Prevalence of HCV-HIV co-infection and risk factors for HCV among injecting drug users in northeast India</p> <p><i>G.K. Medhi, J. Mahanta, S. Phukan, R. Paranjape, G. Thongamba</i> India</p>

WEPE490	<p>A polymorphism linked to <i>RRAS</i>, <i>SCAF1</i>, <i>IRF3</i> and <i>BCL2L12</i> genes is associated with liver cirrhosis in hepatitis C virus carriers</p> <p><i>J. Macias, L.M. Real, A. Caruz, A. Rivero-Juárez, V. Soriano, K. Neukam, A. Rivero, C. Cifuentes, J.A. Mira, J.A. Pineda</i> Spain</p>	WEPE500	<p>HPV vaccination in ARV-treated HIV-infected adolescents and young adults induces strong HPV-specific cell-mediated immune responses</p> <p><i>V. Rainone, D. Trabattoni, F. Penagini, F. Dinello, F. Calascibetta, G.V. Zuccotti, V. Giacomè, A. Viganò, M. Clerici</i> Italy</p>
WEPE491	<p>The largest U.S. retrospective aspartate aminotransferase to platelet ratio index (APRI) score analysis in the HIV/HCV population</p> <p><i>M. Afridi, R. Sison, D. Ali, R. Alcha, R. Hallit, J. Slim, J. Boghossian</i> United States</p>	WEPE501	<p>Cervical cytological abnormalities and human papillomavirus infection in women infected with human immunodeficiency virus in southern India</p> <p><i>S. Thunga</i> India</p>
PE492-498	<p>Sexually transmitted infections (STI) excluding HPV</p>	WEPE502	<p>Prevalence of anal human papillomavirus (HPV) infection in a cohort of Brazilian men</p> <p><i>R. Friedman, J. Coutinho, C. Cunha, C. Barilo, B. Hoagland, S. Cardoso, M. Derrico, R. Moreira, V. Veloso, P. Luz, B. Grinsztejn</i> Brazil</p>
WEPE492	<p>Sexually transmitted infections following HIV diagnosis in Taiwan 2000-2009: a population-based cohort study</p> <p><i>H.-Y. Liu, Y.-C. Chen, C.-Y. Li, N.-Y. Lee, W.-C. Ko, N.-Y. Ko</i> Taiwan, Province of China</p>	PE503	<p>Prophylaxis of HIV associated infections; vaccines e.g. pneumococcal, hepatitis, cotrimoxazole prophylaxis and IPT</p>
WEPE493	<p>CXCL2 concentrations in the serum and cerebrospinal fluid of patients with HIV and syphilis or neurosyphilis</p> <p><i>H.-C. Tsai, I.-T. Chen, P.-Y. Chou, Y.-H. Chen, T.-Y. Hsu, Y.-S. Chen</i> Taiwan, Province of China</p>	WEPE503	<p>Seroprotection and acceptability of one-dose immunization with <i>Neisseria meningitidis</i> C conjugated vaccine among HIV vertically-infected children, in Rio de Janeiro, Brazil</p> <p><i>A.C. Frota, L. Milagres, G. Pereira, A. Cruz, B. Ferreira, D. Menna Barreto, L. Harrison, R.H. Oliveira, T. Abreu, C. Hofer</i> Brazil</p>
WEPE494	<p>Serological screening for syphilis in HIV-infected individuals: is a non-treponemal test adequate in the era of increasing of new syphilis infections?</p> <p><i>G. Chrysos, D. Karageorgopoulos, A. Lazaridou, C. Pouloupoulou, K. Chrysou, P. Chatziastros, E. Friligou, P. Mistylis, A. Sotiropoulos, K. Digalaki, D. Paraskeva</i> Greece</p>	PE504	<p>AIDS related malignancies (KS, lymphoma,) including HHV8 infection</p>
WEPE495	<p>Prevalence of HIV and syphilis infection amongst needle syringe exchange programme attendees at a drop-in centre in Kuala Lumpur</p> <p><i>I. Azwa, A. Azmel, A. Kamarulzaman</i> Malaysia</p>	WEPE504	<p>Association between HMG-CoA reductase inhibitors (statins) use and cancer occurrence among HIV-1 treated patients</p> <p><i>V. Spagnuolo, L. Galli, A. Poli, L. Fumagalli, N. Gianotti, A. Carbone, S. Nozza, S. Bossolasco, A. Lazzarin, A. Castagna</i> Italy</p>
WEPE496	<p>Prevalence and correlates of <i>Chlamydia trachomatis</i> and <i>Neisseria gonorrhoea</i> among men who have sex with men (MSM) in Bangkok, 2006-2010</p> <p><i>J. Tongtoyai, C.S. Todd, S. Pattanasin, W. Chonwattana, S. Chaikummao, P. Wasinrapee, A. Varangrat, S. Lokpichart, T. Holtz, M. Curlin</i> Thailand</p>	PE505-506	<p>Non-AIDS related malignancies</p>
WEPE497	<p>Prevalence of positive syphilis serology in HIV-infected patients: role of routine screening in Thailand</p> <p><i>S. Kukanok, S. Kiertiburanakul</i> Thailand</p>	WEPE505	<p>HIV-related Hodgkin disease shows unique morphological features of macrophage rosetting</p> <p><i>T. Wolf, S. Hartmann, C. Jakobus, C. Stephan, B. Rengstl, H.-R. Brodt</i> Germany</p>
WEPE498	<p>Syphilis incidence and associated risk factors among men who have sex with men (MSM) in Bangkok, Thailand</p> <p><i>W. Thienkrua, C.S. Todd, W. Chonwattana, S. Chaikummao, W. Wimonasate, J. Tongtoyai, P. Luechai, A. Chitwarakorn, C.E. Rose, F. van Griensven, M.E. Curlin, T.H. Holtz</i> Thailand</p>	WEPE506	<p>Increased risk of cancer among HIV-positive women in British Columbia, Canada: importance of targeted screening and detection programs</p> <p><i>A. Cescon, K.A. Salters, W. Zhang, D. Money, M. Murray, A. Coldman, G.S. Ogilvie, J. Hamm, C.G. Chiu, J.S.G. Montaner, S.M. Wiseman, R.S. Hogg, N. Pick</i> Canada</p>
PE499-502	<p>HPV (men and women) diagnosis, therapy, prevention, monitoring, anal and cervical cancer</p>	PE507-510	<p>Treatment strategies for first line therapy including management of late presenters</p>
WEPE499	<p>How antiretroviral therapy can foster the adherence of women to a cytology-based cervical screening program in a rural hospital in Zambia</p> <p><i>E. Facelli, A. Faravelli, S. Guzzetti, L. Viberti, S. Arnaud, M. Barbero, F. Sopracordevole, E. Ferrario, E. Lungu, T. Beia</i> Italy</p>	WEPE507	<p>Evaluation of treatment outcomes on first-line regimens in PEPFAR clinics in Uganda: predictors of treatment success from RV288 analyses</p> <p><i>K.W. Crawford, S. Wakabi, H. Kibuuka, F. Magala, M. Liu, T. Hamm</i> United States</p>
		WEPE508	<p>Trends in adoption of WHO ART guidelines and use of first-line antiretroviral therapy in developing countries (2006-2012)</p> <p><i>V. Habiyembere, B. Dongmo-Nguimfack, F. Renaud-Thery, N. Ford, J. Perriens, M. Doherty, M. Vitoria</i> Switzerland</p>

WEPE509	<p>Interpreting reasons for choosing and changing drug regimens in observational cohort studies: the case of ritonavir-boosted atazanavir (ATV/r) vs efavirenz (EFV) based first-line regimens</p> <p><i>I. Jarrin, S. Moreno, CoRIS</i> Spain</p>	WEPE517	<p>Second-line antiretroviral therapy in HIV-infected patients in Asia: results from the TREAT Asia HIV Observational Database</p> <p><i>V.K. Nguyen, V.H. Bui, N. Durier, B. Sim, I. Azwa, D. Boettiger, A.Y.M. Chen, P.C.K. Li, N. Kumarasamy, R. Chaiwarith, O.T. Ng, S. Kiertiburanakul, S. Pujari, J.Y. Choi, T.P. Merati, S. Vonthanak, F. Zhang, R. Ditangco, S. Oka, P. Kantipong, W. Ratanasuwan, E. Yuniastuti, M. Mustafa, T.T. Pham, K. Ruxrungtham</i> Thailand</p>
WEPE510	<p>The effect of adherence to guidelines on outcome of initial antiretroviral therapy: a French cohort study</p> <p><i>L. Cotte, T. Bénet, P. Vanhems, C. Brochier, T. Perpoint, P. Mialhes, A. Boibieux, F. Ader, T. Ferry, F. Biron, D. Peyramond, C. Chidiac, Lyon HIV Cohort Study Group</i> France</p>	WEPE518	<p>The inhibitory effect of CCR5 antagonist maraviroc on Fas and caspase dependent pathways in CD4+ T cells</p> <p><i>R. Minami, S. Takahama, E. Nakashima, M. Yamamoto</i> Japan</p>
PE511-516	<p>Simplification strategies (induction/maintenance, fixed dose combinations, bPI monotherapy and NRTI-sparing regimens)</p>	WEPE519	<p>Etravirine 200mg twice-daily combined with atazanavir/ritonavir 300/100mg or 400/100mg once-daily in treatment-experienced patients: primary 48-week efficacy and safety analysis of the TEACH trial</p> <p><i>C. Orrell, F. Felizarta, A. Nell, T.N. Kakuda, L. Lavreys, S. Nijs, L. Tambuyzer, R. Van Solingen-Ristea, F.L. Tomaka</i> South Africa</p>
WEPE511	<p>Safety and efficacy of maraviroc-raltegravir combination following 6 months induction with maraviroc-raltegravir-tenofovir-emtricitabine in naïve HIV-1-infected patients with CCR5 virus: interim analysis of the No Nuc No Boost study</p> <p><i>L. Cotte, J. Durant, C. Brochier, P. André, J. Cottalorda, P. Pradat, P. Vanhems, P. Dellamonica</i> France</p>	WEPE520	<p>Trend and determinants of loss to follow up (LTFU) and early mortality from antiretroviral treatment outpatient clinics in Vietnam: implications for program evaluation</p> <p><i>D.A. Tran, A. Shakeshaft, A.D. Ngo, L. Zhang</i> Australia</p>
WEPE512	<p>RADAR study: week 48 safety and efficacy of raltegravir combined with boosted darunavir compared to tenofovir/emtricitabine combined with boosted darunavir in antiretroviral-naïve patients. Impact on bone health</p> <p><i>R. Bedimo, H. Drechsler, J. Cutrell, M. Jain, P. Tebas, N. Maalouf</i> United States</p>	WEPE521	<p>Infrequent use of third-line therapy in Latin America: data from the CCASANet cohort</p> <p><i>C.T. Cesar, B. Shepherd, C. Jenkins, B. Grinsztejn, M. Wolff, J.W. Pape, D. Padgett, J. Sierra Madero, E. Gotuzzo, V.I. Fink, C. Mc Gowan, P.E. Cahn</i> Argentina</p>
WEPE513	<p>Safety and efficacy of efavirenz/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen in HIV-1-infected naïve patients</p> <p><i>S. Gallien, P. Flandre, N. Nguyen, C. Lascoux, N. De Castro, S. Ferret, F. Taieb, G. Walckenaer, J.-M. Molina, C. Delaugerre</i> France</p>	WEPE522	<p>Proposed clinical score to predict etravirine susceptibility after a virologic failure to NNRTIs</p> <p><i>E. Cordova, N. Porteiro, E. Loiza, H. Mingrone</i> Argentina</p>
WEPE514	<p>Randomised study to evaluate lopinavir/ritonavir vs. darunavir/ritonavir monotherapies as simplification of triple therapy regimens</p> <p><i>J.R. Santos, J. Moltó, J.M. Llibre, D. García-Rosado, I. Bravo, J.A. Muñoz-Moreno, N. Pérez-Alvarez, R. Paredes, B. Clotet</i> Spain</p>	WEPE523	<p>Prevalence of rilpivirine and etravirine resistance mutations in HIV-1 non-B subtypes infected patients failing to non-nucleoside transcriptase inhibitor-based therapies in Mali</p> <p><i>A.I. Maiga, F. Daou, A. Balde, D.B. Fofana, B. Traore, Y. Traore, I.A. Maiga, M. Cisse, M.Y. Maiga, H.A. Traore, A. Sylla, O. Koita, C. Katlama, V. Calvez, A.-G. Marcelin, R. Murphy</i> Mali</p>
WEPE515	<p>Intelence and darunavir Once a Day Study (INROADS): a multicenter, single-arm, open-label study of once daily combination of etravirine (ETR) and darunavir/ritonavir (DRV/r) as dual therapy in early treatment-expe</p> <p><i>P. Ruane, C. Brinson, P. Kumar, E. Dejesus, R. Ryan, M. Cho, D. Anderson</i> United States</p>	PE524-528	Adherence
WEPE516	<p>Raltegravir/etravirine dual therapy as a virologically safe treatment option in suppressed HIV-1-infected patients without previous NNRTI failure</p> <p><i>R. Calin, M.-A. Valantin, A. Simon, L. Paris, R. Tubiana, L. Schneider, H. Stitou, C. Delanoe, M. Wirlden, R. Agher, C. Katlama</i> France</p>	WEPE524	<p>HIV disclosure and its effect on treatment outcomes in HIV-infected Thai children and adolescence</p> <p><i>C. Sirikum, J. Sophonphan, T. Chuanjaroen, S. Lakonphon, A. Srimuan, P. Chusug, W. Prasitsuebsai, T. Puthanakit, J. Ananworanich, T. Bunupuradah, HIV-NAT 015 Study Team</i> Thailand</p>
PE517-523	<p>Management strategies for treatment experienced patients</p>	WEPE525	<p>Comparison of adherence monitoring tools and correlation to virologic failure in a pediatric HIV clinical trial</p> <p><i>J. Intasan, T. Bunupuradah, S. Vonthanak, P. Kosalaraksa, Y. Jiriyapongpaiboon, S. Kanjanavanit, C. Ngampiyaskul, J. Wongsawat, W. Luesomboon, T. Apornpong, J. Ananworanich, T. Puthanakit, PREDICT Study Group</i> Thailand</p>

WEPE526 **Evaluation of a comprehensive strategy to measure pediatric adherence to antiretroviral therapy in Kenya**
R. Vreeman, W. Nyandiko, H. Liu, W. Tu, J. Slaven, S. Ayaya, M. Scanlon, T. Inui
 United States

WEPE527 **Antiretroviral therapy adherence patterns among HIV-infected Kenyan children**
R. Vreeman, W. Nyandiko, H. Liu, W. Tu, J. Slaven, S. Ayaya, M. Scanlon, T. Inui
 United States

WEPE528 **The role of early viral load monitoring to improve adherence to antiretroviral therapy**
S.J. Reynolds, K. Newell, G. Nakigozi, L. Chang, T. Quinn, R. Gray, A. Ndyababo, R. Galiwango, V. Kiggundu, D. Serwadda
 Uganda

Track C > Prevention Science

PE529-530 Prevention in prison settings

WEPE529 **Complex health challenges facing HIV-positive individuals with a history of incarceration in British Columbia, Canada**
K. Salters, Z.-S. Cui, H. Samji, W. Small, Y. Chen, J. Montaner, R. Hogg
 Canada

WEPE530 **Establishment of positive club for people live with HIV/AIDS in Mashhad central prison**
F. Jalali, A. Hasani
 Islamic Republic of Iran

PE531-556 Prevention among MSM

WEPE531 **Condom use among men who have sex with men and transgenders in Jakarta, Indonesia**
I. Safika, T. Johnson
 Indonesia

WEPE532 **Advantages of rapid tests for promoting HIV testing and linkage to care among men who have sex with men in China**
D. Zhang, J. Qi, J. Sun
 China

WEPE534 **Factors associated with HIV risk perception among men who have sex with men in Nigeria**
G.I. Fluwa, S.B. Adebajo, I. Kawu, O. Obianwu, B. Ahonsi
 Nigeria

WEPE535 **The informal use of HIV antiretroviral medications for HIV prophylaxis among Australian gay men remains low**
L. Zablotska, M. Holt, G. Prestage, L. Mao, J. de Wit, A.E. Grulich
 Australia

WEPE536 **Potential impact of human papillomavirus (HPV) vaccination among HIV-positive and HIV-negative homosexual men: vaccine-preventable anal HPV types in the SPANC study**
L.M. Poynten, S. Tabrizi, F. Jin, A. Hurley, R. Hillman, D. Templeton, D. Machalek, A. Cornall, J. Roberts, S. Garland, C. Fairley, A. Grulich, on behalf of the SPANC Study Team
 Australia

WEPE537 **Effectiveness of HIV risk reduction interventions among men who have sex with men in Asian countries: a systematic review and meta-analysis**
L. Yin, H. Lu, Y. Liu, K. Dahiya, W. Fan, L. Zhang, Y. Ruan, Y. Shao, H.-Z. Qian, S.H. Vermund
 United States

WEPE538 **Characteristics and sexual risk behaviours of men who have sex with men (MSM) who use cell phones and Internet to seek male sexual partners in Chennai, India**
M. Shanmugam, M. McInnis, R. Nelson, V. Chakrapani, T. Kershaw
 India

WEPE539 **Sexual identity and HIV risk behaviours, including multiple sexual partnerships, among men who have sex with men (MSM) in Vietnam: findings from a web-based cross-sectional study**
M.C. Garcia, Q.L. Duong, P.R. Ward, S.B. Meyer
 United States

WEPE540 **'Never testing for HIV' among men who have sex with men in Vietnam: results from an internet-based survey**
M.C. Garcia, Q.L. Duong, S.B. Meyer, P.R. Ward
 United States

WEPE541 **Factors associated with condom breakage among men who have sex with men (MSM) in three south Indian states: findings from a cross-sectional bio-behavioural survey**
S. Ramanathan, L. Ramakrishnan, P. Goswami, D. Yadav, B. George, S. Sen, V. Chakrapani, R. Paranjape, T. Subramanian, H. Rachakulla
 India

WEPE542 **'So?...am i supposed to use condoms forever?' An investigation of perceived sexual risk in romantic relationships among young MSM**
L. Young, P. Sullivan, R. Stephenson
 United States

WEPE543 **Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men and transgender women in Peru**
E.G. Ferro, D. Weikum, P. Vagenas, M.M. Copenhaver, P. Gonzales, J. Peinado, J.R. Lama, J. Sanchez, F.L. Altice
 United States

WEPE544 **Knowledge about HIV preventive measures among MSM using internet-based social networks in Brazil**
A.R.S. Périssé, B. Grinsztejn, R.C. Sineath, V. Veloso, S.A. Lippman, S. Buchbinder, P.S. Sullivan
 Brazil

WEPE545 **Influence of sexual minority stigma and HIV-related stigma on mental health: testing the minority stress model among men who have sex with men in India**
V. Chakrapani, M. Shanmugam, M. Sivasubramanian, M. Samuel, L. Carmen, P.A. Newman, P. Dhall, J. Syed
 India

WEPE546 **Influence of transgender identity stigma and HIV-related stigma on mental health: testing the minority stress model among hijras/transgender women in India**
V. Chakrapani, M. Shanmugam, M. Sivasubramanian, M. Samuel, L. Carmen, P.A. Newman, S.R. Karmakar, J. Syed
 India

WEPE547	<p>A randomized clinical trial of two interventions to reduce HIV risk and substance use among highly vulnerable MSM</p> <p><i>S.P. Kurtz, M.E. Buttram, R.D. Stall, H.L. Surratt</i> United States</p>	WEPE558	<p>Estimates of contraceptive use among female sex workers in Nairobi: results from a respondent-driven sampling study</p> <p><i>J. Oka, E. Yam, A. Kim, W. Tun, M. Sheehy, H. Mutua, N. Muraguri, B. Mundia, D. Broz, R. Kaiser, S. Dadabhai, H.F. Raymond, S. Geibel</i> Kenya</p>
WEPE548	<p>Human rights violations as a barrier to implementing HIV prevention programs for key populations: the case of men who have sex with men (MSM) in Ulaanbaatar, Mongolia</p> <p><i>S. Stromdahl, F. Yasin, A. Delegchoimbol, N. Jamiyanjamts, K. Mason, S. Baral</i> United States</p>	WEPE559	<p>The cycle of transactional sex, HIV, physical violence and poor mental health: results from a nationally representative survey from Zimbabwe</p> <p><i>F.M. Cowan, R. Buzdugan, S. Chidiya, O. Mundida, O. Mugurungi, M. Nekkanti, S. Mtetwa, C. Watadzaushe, J. Dirawo, B.O. Tambashe, C. Benedikt</i> United Kingdom</p>
WEPE549	<p>Sexual risk behaviour among MSM in Gujarat, India</p> <p><i>B. Modi, R. Patel, U. Joshi, U. Oza</i> United States</p>	WEPE560	<p>Supporting HIV prevention among Kenyan male sex workers: determination of initial lubricant requirements through national quantification</p> <p><i>W. Waitthaka, C. Muiva, G. Githuka, J. Chimumbwa</i> Kenya</p>
WEPE550	<p>Determinants of HIV infection among MSM in Gujarat, India</p> <p><i>B. Modi, U. Joshi, R. Patel, U. Oza</i> United States</p>	WEPE561	<p>Condom negotiation skills are associated with condom use and may facilitate HIV prevention: a study among female sex workers in the Gambia</p> <p><i>A. Grosso, E. Lei, S. Ketende, K. Mason, S. Peitzmeier, N. Ceesay, D. Diouf, J. Loum, D. Deen, F. Drame, S. Baral</i> United States</p>
WEPE551	<p>HIV incidence rates and risk factors for infection in an open cohort study of homosexual and bisexual men: Project Horizonte, Brazil (1994-2011)</p> <p><i>A.P. Silva, M. Greco, M.A. Fausto, D. Greco, M. Carneiro, Project Horizonte</i> Brazil</p>	WEPE562	<p>Factors associated with HIV testing among female sex workers in the Gambia</p> <p><i>A. Grosso, S. Ketende, K. Mason, S. Peitzmeier, N. Ceesay, D. Diouf, J. Loum, D. Deen, F. Drame, S. Baral</i> United States</p>
WEPE552	<p>Minority stress and intimate partner violence among gay and bisexual men</p> <p><i>C. Finneran, R. Stephenson</i> United States</p>	WEPE563	<p>Sex work, risk environment and HIV incidence among people who inject drugs in Vancouver, Canada</p> <p><i>L. Ti, K. Shannon, A. Simo, E. Wood, J. Montaner, T. Kerr</i> Canada</p>
WEPE553	<p>Recent receipt of intimate partner violence is associated with increased reporting of recent number of anal sex partners among gay and bisexual men</p> <p><i>C. Finneran, R. Stephenson</i> United States</p>	WEPE564	<p>The contribution of emotional partners to sexual risk taking and violence among female sex workers in Mombasa, Kenya: a cohort study</p> <p><i>S. Luchters, M. Richter, W. Bosire, G. Nelson, N. Kingola, X. Zhang, M. Temmerman, M.F. Chersich</i> Australia</p>
WEPE554	<p>Correlation of alcohol, high-risk sexual behaviours among men who have sex with men in Peru: implications for future HIV prevention intervention</p> <p><i>K. Ludford, P. Vagenas, J. Lama, J. Peinado, P. Gonzales, R. Leiva, M. Pun, J. Sanchez, F.L. Altice</i> United States</p>	PE565-579	<p>Prevention among IDU and non-IDU substance using populations, including alcohol abusers</p>
WEPE555	<p>Rectal microbicide acceptability and likelihood of use among young men who have sex with men: variations by partner type in a placebo gel trial in the United States</p> <p><i>R. Giguere, C. Dolezal, J. Bauermeister, C.-S. Leu, J. Valladares, T. Frasca, I. Febo, R. Cranston, K. Mayer, I. McGowan, A. Carballo-Diéguez</i> United States</p>	WEPE565	<p>Hazardous and harmful alcohol use among female sex workers in Kenya, associations with risky sexual behaviour and HIV incidence: a cohort study</p> <p><i>S. Luchters, W. Bosire, N. Kingola, M. Temmerman, M.F. Chersich</i> Australia</p>
WEPE556	<p>Characterizing the incidence of HIV, associated risk factors and prevention needs among a cohort of men who have sex with men in Senegal</p> <p><i>F. Drame, E. Crawford, D. Diouf, S. Mbaye, M. Ndaw, A.K. Diongue, W. Cisse, O.K. Camara, L.F. Dieng, G. Batista, P. Sagna, S. Baral</i> Senegal</p>	WEPE566	<p>High prevalence of illicit drug use among patients with HIV-1 infection in a large urban HIV clinic in Tokyo</p> <p><i>T. Nishijima, H. Gatanaga, H. Komatsu, M. Takano, M. Ogane, K. Ikeda, S. Oka</i> Japan</p>
PE557-564	<p>Prevention among sex workers</p>	WEPE567	<p>Measuring progress on harm reduction: improving guidance on measuring and setting targets for HIV prevention, treatment and care for people who inject drugs</p> <p><i>A. Verster, B. Mathers</i> Switzerland</p>
WEPE557	<p>Health-seeking behaviour among female sex workers (FSWs) in Lagos State Nigeria</p> <p><i>O.S. Asaolu, O.T. Afolabi, O. Ezire, U. Nwafor, T. Adenipekun, O. Olawande</i> Nigeria</p>		

WEPE568	<p>Current opioid injecting users and methadone maintenance enrollment in Vietnam: a cross-sectional study</p> <p><i>N. Nguyen, R. Detels</i> Vietnam</p>	WEPE580	<p>Prevalence and HIV risk-related correlates of emotional, physical and sexual violence among women at risk for HIV in the United States: data from HPTN 064 (The Women's HIV SeroIncidence Study)</p> <p><i>B.E.E. Montgomery, A. Rompalo, J. Hughes, J. Wang, D. Haley, L.E. Soto-Torres, W. Chege, J.E. Justman, S.L. Hodder, on behalf of the HIV Prevention Trials Network (HPTN) 064 Study Team</i> United States</p>
WEPE569	<p>Relationship between food insecurity and mortality among HIV-positive injection drug users receiving antiretroviral therapy in British Columbia, Canada</p> <p><i>A. Anema, K. Chan, Y. Chen, S.D. Weiser, J. Montaner, R. Hogg</i> Canada</p>	WEPE581	<p>Developing WHO guidance on viral hepatitis B and C for people who inject drugs</p> <p><i>N. Walsh, A. Verster, M. Rodolph</i> Cambodia</p>
WEPE570	<p>Drug users' willingness to encourage risk network members to receive a HIV vaccine and/or participate in HIV vaccine clinical trials: a social network analysis</p> <p><i>A.M. Young, D.S. Halgin, R.J. DiClemente, H.L.F. Cooper, C.E. Sterk, J.R. Havens</i> United States</p>	PE582-588	<p>Prevention among emerging vulnerable populations</p>
WEPE571	<p>Harm reduction: Malaysia experiences</p> <p><i>F. Yuswan, S. Ngadiman</i> Malaysia</p>	WEPE582	<p>Condom use and perception: the challenges to HIV/AIDS prevention among the elderly In Nigeria</p> <p><i>E. Uchenna, O. King, R. Opara, I. Ngozi</i> Nigeria</p>
WEPE572	<p>Mixing sex and drugs: socio-demographic factors associated with sexual risk behaviour among PWID. Findings from the Hridaya baseline study in India</p> <p><i>V. Arumugam, K. Biswas, C. Sharma, S. Rakesh, S. Mehta, J. Robertson</i> India</p>	WEPE583	<p>Interplay of gender, age and psychological resistance to voluntary counselling and testing of HIV/AIDS among students of tertiary institutions in Kano state, Nigeria</p> <p><i>A.S. Haruna, M.U. Tambawal</i> Nigeria</p>
WEPE573	<p>Determinants of VCT uptake among clients of Needle Syringe Exchange Program (NSEP) in Kelantan</p> <p><i>S.A. Termizi, W.M.Z. Wan Mohamad</i> Malaysia</p>	WEPE584	<p>Characteristics of HIV-positive American Indians ? Arizona, 1990-2012</p> <p><i>S. Yasmin, R. Mdodo, H. Huentelman, P. Bloomquist, M. Taylor</i> United States</p>
WEPE574	<p>Retention of participants in opiate substitution programs in low- and middle-income countries: an international systematic review</p> <p><i>D.C. Des Jarlais, J. Feelemyer, K. Arasteh, A. Abdul-Quader, H. Hagan</i> United States</p>	WEPE585	<p>PSI Côte d'Ivoire's testing and counseling (HTC) strategy for Uniform Services Personnel: from partnership to ownership</p> <p><i>K. Haudy Stanislas Arsene, PSI-TEAM Study Group</i> Ivory Coast</p>
WEPE575	<p>Changes in quality of life (QOL) and addiction severity index (ASI) among participants in opiate substitution programs in low- and middle-income countries: an international systematic review</p> <p><i>D.C. Des Jarlais, J. Feelemyer, K. Arasteh, A. Abdul-Quader, H. Hagan</i> United States</p>	WEPE586	<p>Female partners of IDU are under high-risk of HIV infection as HIV transmission shift from injection drug users to heterosexual contact: Republic of Georgia, 2002-2011</p> <p><i>O. Chokoshvili, N. Chkhartishvili, N. Chokoshvili, M. Tsinstadze, T. Tsertsvadze</i> Georgia</p>
WEPE576	<p>Limited access to HIV testing and HIV care among people who inject drugs in Malaysia: a call to action</p> <p><i>J. Fu, A. Bazazi, A. Kamarulzaman, J. Wickersham, F. Altice</i> United States</p>	WEPE587	<p>Sexual risk behaviour among long distance commercial bus drivers in urban Lagos, Nigeria</p> <p><i>J.O. Jawando</i> Nigeria</p>
WEPE577	<p>Drug use and injection risk behaviours among female drug users in Malaysia: results from a pilot study</p> <p><i>J. Wickersham, K. Loeliger, V. Pillai, R. Marcus, A. Kamarulzaman, F. Altice</i> United States</p>	WEPE588	<p>Risk factors for mortality among people diagnosed with AIDS at 60 years and above in Brazil</p> <p><i>M. Fonseca, U. Tupinambás, L. Rodrigues, K. Baisley, D. Greco</i> Brazil</p>
WEPE579	<p>Willingness to pay for methadone maintenance treatment in injection-driven HIV epidemics</p> <p><i>B. Tran</i> Vietnam</p>	PE589-591	<p>Use of internet, social media and other e-devices to provide and link to prevention and treatment services</p>
PE580-581	<p>Prevention among populations with multiple co-occurring epidemics/syndemics</p>	WEPE589	<p>'Chem sex': prevalence and correlates of sex while under the influence of recreational drugs among MSM in Malaysia. Findings from the Asian Internet MSM Sex Survey</p> <p><i>S.H. Lim, T.E. Guadamuz, C. Wei, S. Koe</i> Malaysia</p>

WEPE590 **A culturally sensitive online communication campaign to reach hidden men who have sex with men for HIV/STI prevention and testing in Indonesia: TemanTeman.org**
T. Anand, J. Ananworanich, T. Parwati Merati, E. Yuniastuti, D. Imran, C. Nitpolprasert, A.H. Sohn, N. Phanuphak
 Thailand

WEPE591 **Accessing township-based men who have sex with men (MSM) through social networks and mobile phones in Cape Town, South Africa**
B. Brown, E. Batist, B. Kanyemba, A. Scheibe, V. Silenzio, L.-G. Bekker
 South Africa

PE592 Identification of acute and recent HIV infection

WEPE592 **Change in the characteristics of patients at HIV acquisition: results from a cohort study of HIV-seroconverters in Spain**
A. Schiaffino, S. Pérez-Hoyos, J. Del Romero, A. Sanvisens, I. Hurtado, R. Muga, J. Del Amo, P. Garcia de Olalla, I. Alastrue, F. Belda, Spanish Multicenter Study Group of Seroconverters (GEMES)
 Spain

PE593-595 Prevention in positives

WEPE593 **Factors associated with undiagnosed HIV infection among persons living with HIV in Mozambique, 2009**
E.K. Dokubo, R. Shiraiishi, P. Young, J.J. Neal, J. Aberle-Grasse, F. Mbofana
 United States

WEPE594 **Factors influencing access of PLHIV to community home-based care: a mixed method research in Nepal**
A. Shrestha, A. Aryal, K.P. Bista
 Nepal

WEPE595 **Impact of alternative treatment strategies on HIV prevalence in South Africa: a modelling study**
E. Meng, W. Delva, N. Hens
 Belgium

PE596-600 Community-based HIV prevention research designs

WEPE596 **HIV/AIDS prevention among long distance drivers: a comparative study showing progress made over the years**
T.O. Lawoyin, H. Osinowo, O. Lawoyin, T. Balogun
 United States

WEPE597 **Ethical beliefs and attitudes of Malaysian medical students towards individuals with HIV/AIDS**
T. Jae Rene, S. Ahmed Khan, K. Kwee Choy
 Malaysia

WEPE598 **Partner-specific correlates of heterosexual anal intercourse among truck drivers and their wives in south India**
T. Bhatnagar, P.S. Saravanamurthy, R. Detels
 India

WEPE599 **Innovative approaches to community engagement within an HIV prevention needs assessment of men who have sex with men (MSM) in Scotland**
C. Morrison, L. Carroll, D. Clutterbuck, N. Coia, R. McAdams, D. Milne, J. Shanley, A.J. Winter
 United Kingdom

WEPE600 **Venues for meeting sex partners and partner HIV risk characteristics: HIV prevention trials network (HPTN064) women's HIV seroIncidence study (ISIS)**
M. Roman Isler, C. Golin, J. Wang, J. Hughes, J. Justman, D. Haley, A. Adimora, W. Chege, S. Hodder, HIV Prevention Trials Network (HPTN064) Women's HIV SeroIncidence Study (ISIS)
 United States

Track D > Operations and Implementation Research

PE601-602 Models of private-public partnerships for prevention, treatment, care and support (service delivery, financing)

WEPE601 **Oral health status of HIV/AIDS patients in care support centres in Karnataka state of India**
M. Moothedath, G. Shenoy, V. Hegde, HIV Study Group Kerala
 India

WEPE602 **Social entrepreneurship for sexual health (SESH): new organizational and financial models for sustaining HIV testing services**
J. Tucker, K. Muessig, R. Cui, C. Bien, L. Ramon, E. Lo, L. Yang, B. Yang, H. Larson, R. Peeling
 China

PE604-605 Scale up of early infant diagnosis and paediatric treatment: feasibility and operational issues

WEPE604 **Gaps in linkage to antiretroviral therapy among HIV-infected infants and children in Uganda**
P.J. Elyanu, D. Nakanjako, E. Namagala, C. Kiyaga, C.J. Schellack, D. Damba, A. Kekitiinwa, N. Mawani, N. Sewankambo
 Uganda

WEPE605 **Presumptive diagnosis of severe HIV disease: the cornerstone to saving HIV-exposed infants' lives in Lesotho**
A. Tiam, M. Foso, A. Isavwa, O. Oyebanji, A. Ahimbisibwe, I. Seipati
 Lesotho

PE607-609 Impact of introducing point-of-care technologies

WEPE607 **Using finger-prick blood collection samples for the Pima POC CD4 device increases access to CD4 testing**
A.M. Brouillette, E. Chien, W. Nyegenye, J. Lehe, T. Tenywa, J. Grosz
 Uganda

WEPE608 **The introduction of a POC CD4 technology increases patient access to and the impact of CD4 testing**
A. Mwanja, L. Brown, E. Mtumbuka, C. Shayo, L. Vojnov
 Tanzania, United Republic of

WEPE609 **Improving access to care and treatment by strengthening CD4 count testing capacity in rural health districts in Cameroon through point-of-care technology**
M.R. Rioja, E. Mboh Khan, D. Nzuobontane, F. Munyaburanga, T. Pius Muffih, T. Asong
 Cameroon

PE610-611 Strategies to increase access to viral load measurements

WEPE610	<p>Field evaluation of performance of dried blood spots (DBS) from finger-prick for the determination of viral load in a resource-constrained setting in urban and rural Zimbabwe</p> <p><i>S. Mtapuri-Zinyowera, F. Taziwa, C. Metcalf, E. Mbofana, S. De Weerd, L. Flevaud, S. Simons, J.-F. Saint-Sauveur, E. Fajardo</i> Zimbabwe</p>	WEPE620	<p>Improvement of voluntary counseling and testing (VCT) process quality in Rwanda from 2006-2008: effect of pay for performance (P4P)</p> <p><i>J. Condo</i> Rwanda</p>
WEPE611	<p>Implementation of selective viral RNA measurement in patients suspected of failing treatment in resource-limited settings</p> <p><i>G. Buluku, R. Redfield, S. Ojoo, F. Odhiambo, C. Mwachari, J. Ondigo, F. Otieno</i> Kenya</p>	PE621-622	<p>Impact of donor agencies policies on national response</p>
PE612-615	<p>Optimizing the use of clinical lab monitoring in low resources setting</p>	WEPE621	<p>Building on the progress made: ensuring a sustainable HIV/AIDS scenario post-GFATM involvement in Peru</p> <p><i>A. Amaya, D. Balabanova, C. Cáceres</i> United Kingdom</p>
WEPE612	<p>Assessment of virologic, immunologic, clinical and/or adherence criteria for detection of HIV drug resistance in rural Cameroon: data from the Stratall ANRS 12110/ESTHER trial</p> <p><i>C. Boullé, C. Kouanfack, G. Laborde-Balen, A. Fobang Aghokeng, S. Boyer, M.P. Carrieri, S. Kazé, J.-M. Mben, M. Dontsop, B. Spire, M. Peeters, E. Mpoudi-Ngolé, E. Delaporte, C. Laurent, Stratall ANRS 12110/ESTHER Study Group</i> France</p>	WEPE622	<p>Evolving United States trade and aid policies towards Vietnam: do they threaten Vietnam's progress towards scaling up HIV prevention, treatment and care?</p> <p><i>R. Malpani, N.T. Huong, J. Rius Sanjuan, S. Lynch</i> United States</p>
WEPE614	<p>Hematological infant reference ranges and implications for toxicity grading among the pediatric study participants in Botswana</p> <p><i>S. Moyo, G.K. Mayondi, K. Powis, S. Dryden-Peterson, J. Leidner, A. Ogwu, C. Mdluli, M. Diseko, J. Magetse, P.M. Mangwendeza, M. Chishamiso, R. Shapiro, B. Kammerer, J. Makhema, R.M. Musonda, S. Lockman</i> Botswana</p>	PE623	<p>Impact of financial crises on the HIV funding and response</p>
WEPE615	<p>Optimal monitoring strategies for HIV-infected individuals on antiretroviral therapy: a systematic review</p> <p><i>J. Tucker, C. Bien, P. Easterbrook, M. Penzato, M. Doherty, M. Vitoria, R. Peeling</i> China</p>	WEPE623	<p>Building the path to the end of AIDS: how investments in HIV prevention research and development responded to the global economic downturn, new research results and funding trends 2000-2012</p> <p><i>E. Donaldson, K. Fisher, R. Granich, A. Grujovic, T. Harmon, P. Harrison, N. Saelens, M. Warren</i> United States</p>
PE616-620	<p>National and international financing initiatives, including cross national comparisons of financing initiatives</p>	PE624	<p>Leveraging global health initiative funds for strengthening other health outcomes and health systems</p>
WEPE616	<p>Evaluating Global Fund country disbursements from 2003 - 2012 against a prioritization score based on disease burden and income level</p> <p><i>K.H. Tram</i> United States</p>	WEPE624	<p>Could this be the most effective way for ensuring accountability of HIV/AIDS funds/grant? Target costing and activity-based funding: the budgetary approach for HIV/AIDS program</p> <p><i>B. Lusambili, S. Kamuti, N. Kivuva</i> Kenya</p>
WEPE617	<p>Sustainable health financing in Africa: measuring domestic resources and the Abuja commitment</p> <p><i>K.H. Tram</i> United States</p>	PE625-627	<p>Building country ownership in HIV care and prevention</p>
WEPE618	<p>Development of a predictive model to identify high cost users of antiretroviral drugs in the adult HIV/AIDS population: who are the most expensive and why?</p> <p><i>C. Velasco Muñoz, I. Perez, M. Martí, P. Imma, A. Trilla, J.M. Gatell Artigas</i> Spain</p>	WEPE625	<p>"So yeah, it's certainly a challenge. Because the basics on which you are building are very weak": qualitative perspectives on PEPFAR's transition to country ownership in Mozambique</p> <p><i>P. Hazelton, A. Swidler, S. Shade</i> United States</p>
WEPE619	<p>Financing free and universal access to antiretroviral drugs in the long-run: ART cost evolution in Brazil</p> <p><i>C. Meiners-Chabin</i> Brazil</p>	WEPE626	<p>Bridging the resource gap for sustainable OVC response in Nigeria: results of collaborative efforts</p> <p><i>S.M. Amahson, O. Doherty, Z. Kpamor, G. Garnwa, O. Onifade</i> Nigeria</p>
		WEPE627	<p>Exploring the meaning and limits of 'country ownership' in South Africa: experiences with 11 diverse externally-funded projects on HIV prevention, treatment and policy</p> <p><i>A.N. Parsons, C. Zarowsky</i> South Africa</p>
		PE628-636	<p>Linking operational and implementation research to changes in policy and practice</p>
		WEPE628	<p>Prioritizing strategies to address voluntary HIV counseling and testing [VCT] among long distance and commercial drivers in Ibadan, Nigeria</p> <p><i>T.O. Lawoyin, O. Lawoyin</i> United States</p>

WEPE629	<p>Uptake of 2010 WHO ARV recommendations in Zambia, Kenya and Uganda</p> <p><i>A. Gasasira, S. Masters, B. Decenso, E. Gakidou</i> United States</p>	WEPE639	<p>Innovations for improving tuberculosis case-finding, prevention and treatment among PLHIV in resource-constrained settings</p> <p><i>C. Catalani, E. Green, D. Lameck, P. Biondich</i> United States</p>
WEPE630	<p>The GESIDA project of quality in care of HIV patients: measurement of 16 relevant indicators</p> <p><i>M.A. von Wichmann, M. Riera, H. Esteban, I. Suarez, J.R. Blanco, E. Valencia, R. Palacios, F. Lozano, A. Ocampo, C. Amador, C. Sarasqueta, J. Locutura, F. Rodriguez Arrondo, M.A. Garcia Gonzalo</i> Spain</p>	WEPE640	<p>The use of quality assurance processes in identifying barriers to district graduation from intensive partner technical assistance in the Zambia Prevention Care and Treatment supported HIV/AIDS program in Zambia</p> <p><i>P. Koni, L. Nyirenda, P. Kasonde, A. Musonda, M. Welsh</i> Zambia</p>
WEPE631	<p>Demand for prevention of mother to child HIV transmission services in Zimbabwe: the role of fees and prices</p> <p><i>N.L. Czaicki, S. Bautista-Arredondo, S.I. McCoy, R. Buzdugan, F.M. Cowan, A. Mushavi, A. Mahomva, N.S. Padian</i> United States</p>	WEPE641	<p>Real-time source document verification improves the quality of data management in HIV clinical trials</p> <p><i>O. Butterworth, P. Reksirikul, K. Pongjit, S. Prasertthanawut, T. Suwanlerk, T. Jupimai, J. Wongsabut, A. Avihingsanon, J. Ananworanich</i> Thailand</p>
WEPE632	<p>Not a 'minor' issue: does HIV prevention programming address the vulnerabilities of adolescent MSM and transgenders under 18 years? Findings from the Pehchan midline study in India</p> <p><i>K. Biswas, N. Mattipalli, A. Biswas, B. Uberhande, S. Mehta, S. Rakesh, J. Robertson</i> India</p>	WEPE642	<p>Assessing HIV drug resistance early warning indicators (EWIs) at facilities providing antiretroviral treatment (ART) in Tshwane, South Africa: what are the implications for ART programme management?</p> <p><i>H.-F. Kinkel, S. Memon, T. Marcus, S. Johnson</i> South Africa</p>
WEPE633	<p>Understanding barriers faced by transgender and hijra communities in India to accessing gender reassignment services: research from the Global Fund-supported Pehchan program</p> <p><i>Y. Singh, V. Chakrapani, A. Aher, S. Shaikh, H. Khosa, S. Mehta, J. Robertson, S. Rakesh</i> India</p>	WEPE643	<p>Scaling up health information systems to improve vital statistics: implementing a national data mortality system in Mozambique</p> <p><i>A. Campione, C. Seebregts, R. Pastore, J.L. Nhampossa, C. Baloi, A. Covane, P. Hazelton, S. Shade</i> United States</p>
WEPE635	<p>Dispensing-based information system at ART pharmacies and its potential for enforcing treatment guidelines in resource-limited settings: the Ethiopian experience</p> <p><i>H. Tadege, N. Mekonnen</i> Ethiopia</p>	WEPE644	<p>From data to decision-making: implementation of an ART logistics management information system in the Kingdom of Swaziland</p> <p><i>G. Mekonnen, T. Sigudla, G. Young, K. Matshotyana</i> Swaziland</p>
WEPE636	<p>Availability of clinical and laboratory information to monitor response to antiretroviral therapy in three Sub-Saharan African countries</p> <p><i>H. Duber, B. Decenso, A. Gasasira, T. Odeny, S. Masters, R. Burstein, R. Conner, E. Dansereau, M. Hanlon, S. Kumar, K. Moore, C. Kisia, P. Njuguna, J. Achan, G. Ikilezi, F. Masiye, E. Gakidou</i> United States</p>	WEPE645	<p>Improving the pharmaceutical management information system for antiretroviral therapy in Lesotho: a computerized solution</p> <p><i>T. Ramanemane, I. Tshabalala, T.T. Sepetla, N. Hoohlo-Khotle, L. Mabesa</i> Lesotho</p>
PE637	<p>Capacity building initiatives for implementation science and operational research</p>	WEPE646	<p>Enhancing capacity of the national laboratory logistics management information systems in strengthening access to ART services in resource-limited settings: lessons from Lesotho</p> <p><i>N. Hoohlo-Khotle, T.T. Sepetla, R. Ranyamatsane, D. Mothabeng, P. Motemekoane</i> Lesotho</p>
WEPE637	<p>Evaluation of cognitive performance among HIV-infected and uninfected women in rural Gabon</p> <p><i>J. Burqos-Soto, A. Mbongo, H. Mokri, H. Amieva, R. Becquet</i> France</p>	WEPE647	<p>Re-tooling data quality: implementation of an automated validation tool to improve data quality in large-scale HIV interventions for female sex workers under the Avahan programme in Andhra Pradesh, India</p> <p><i>P. Prabhakar, R. Ramakrishna, S.J. Prashanth, K. Jayakumar, C. Parthasarathy, J. Robertson</i> India</p>
PE638-655	<p>HIV/AIDS data management information and electronic systems for monitoring and evaluation, to facilitate uptake of services and improve outcomes</p>	WEPE648	<p>Use of computer-based tool to monitor World Health Organization early warning indicators for ART: a case study of Liverpool VCT Care & Treatment in Kenya</p> <p><i>J. Warero, T. Njoroge, C. Muiva, S. Abuga, J. Chimubwa, P. Njeru, N. Njeru</i> Kenya</p>
WEPE638	<p>Decreasing the proportion of patients lost to follow-up at an out-patient HIV clinic in eastern Uganda</p> <p><i>M. Kakinda, J.C. Opio, J.K.B. Matovu</i> Uganda</p>		

- WEPE649 **A novel approach to surveillance supervision: SIMS surveillance module**
S. Venkatesh, Y. Raj, P. Kumar, K. Dindi, P. Harvey, D.S. Joshi
India
- WEPE650 **Improving turn-around time for HIV DNA PCR lab results for early infant diagnosis in Kenya**
B. Gautney, S. Finocchiaro-Kessler, V. Okoth, J. Dougherty, E. Serem, K. Clark, S. Khamadi
United States
- WEPE651 **Linked data systems for longitudinal monitoring and evaluation of the continuum of HIV care in British Columbia**
B. Nosyk, J. Montaner, G. Colley, K. Chan, K. Heath, B. Yip, H. Samji, M. Gilbert, R. Barrios, R. Gustafson, V. Lima, R. Hogg, STOP HIV/AIDS Study Group
Canada
- WEPE652 **Nationwide strategic information management system: improving the quality of data for monitoring program outcomes**
S. Venkatesh, U. Jha, Y. Raj, A.B. Sahu, P. Harvey, D.S. Joshi
India
- WEPE653 **Identifying facilitators and barriers to optimal data-use for elimination of mother to child transmission of HIV (EMTCT) in Zambia: a qualitative assessment**
J. Menke, R. Nswana, EGPAF, Strategic Information and Evaluation Unit, Zambia
Zambia
- WEPE654 **No-cost tracking system for follow-up of HIV-positive pregnant women and their babies till 18 months in Chandrapur district, Maharashtra, India. A pilot by Maharashtra State AIDS Control Society (MSACS)**
A.S. Hegde, T.M. Rane
India
- WEPE655 **Implementing electronic medical records in HIV care and treatment: experiences and lessons learnt in eastern and central regions in Kenya**
P. Munyao, M. Kithaka, W. Watembo, A. Kisilu, C. Rukunga, D. Okubasu, M. Kabue, P. Wamae, I. Malonza
Kenya